Literature DB >> 8098880

Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: effect of sensitization (priming) with a dopaminergic agonist.

M Morelli1, F E Pontieri, I Linfante, F Orzi, G Di Chiara.   

Abstract

In rats bearing unilateral 6-hydroxydopamine (6-OHDA) lesions of the dopaminergic nigro-striatal neurons, a single administration of a D-2 agonist (LY 17155) potentiates the contralateral turning induced by a D-1 agonist (SKF 38393). To identify the neural substrate of this form of sensitization (priming), we studied the local cerebral glucose utilization (lCMRglc) in 6-OHDA lesioned animals treated, 3 days apart, as follows: (1) saline-saline, (2) LY 171555-saline, (3) saline-SKF 38393 and (4) LY 171555-SKF 38393. The unilateral 6-OHDA lesion per se (Sal-Sal) produced increases in lCMRglc in the globus pallidus (GP) and in the lateral habenula (LH) of the lesioned hemisphere. lCMRglc in LY-Sal group were similar to those measured in the Sal-Sal group. Administration of SKF 38393 to drug-naïve rats (Sal-SKF) abolished the lesion-induced metabolic asymmetry in the LH but did not have any effect on the GP; furthermore, it increased lCMRglc in the substantia nigra pars reticulata (SNr) of the lesioned side. After priming with LY 171555, administration of SKF 38393 (LY-SKF) produced marked metabolic asymmetries by increasing lCMRglc in the SNr and entopeduncular nucleus (EP), and decreasing it in the LH of the lesioned side. These changes were also significant when compared to the corresponding values of the other experimental groups. Again, in LY-SKF group no modification of the lesion-induced metabolic asymmetry in the GP was found.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098880     DOI: 10.1002/syn.890130309

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  7 in total

Review 1.  Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

Authors:  Agnès Nadjar; Charles R Gerfen; Erwan Bezard
Journal:  Prog Neurobiol       Date:  2008-09-30       Impact factor: 11.685

2.  Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease.

Authors:  Cindy Casteels; Erwin Lauwers; Guy Bormans; Veerle Baekelandt; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-29       Impact factor: 9.236

3.  In vivo imaging of disturbed pre- and post-synaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease.

Authors:  Abesh Kumar Bhattacharjee; Lindsey M Meister; Lisa Chang; Richard P Bazinet; Laura White; Stanley I Rapoport
Journal:  Neuroimage       Date:  2007-06-27       Impact factor: 6.556

Review 4.  The 6-hydroxydopamine model of Parkinson's disease.

Authors:  Nicola Simola; Micaela Morelli; Anna R Carta
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

5.  Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias.

Authors:  T Hershey; K J Black; M K Stambuk; J L Carl; L A McGee-Minnich; J S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

6.  Prolactin and fMRI response to SKF38393 in the baboon.

Authors:  Brad Miller; Lauren A Marks; Jonathan M Koller; Blake J Newman; G Larry Bretthorst; Kevin J Black
Journal:  PeerJ       Date:  2013-10-29       Impact factor: 2.984

7.  Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Robert Westphal; Camilla Simmons; Michel B Mesquita; Tobias C Wood; Steve C R Williams; Anthony C Vernon; Diana Cash
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.